Home
My Account
About Us
Forum
Contact us
الواجهة العربية
epharmaweb.com
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz
Newsletter

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



EMA approves Silodyx & Urorec for the treat of benign prostatic hyperplasia symptoms


Silodyx & Uroreca are medicines that contain the active substance silodosin. They are available as capsules (yellow: 4 mg; white: 8 mg).

This drug is used to treat the symptoms of benign prostatic hyperplasia (BPH, an enlarged prostate gland). The prostate gland is an organ found at the base of the bladder in men. When enlarged, it can cause problems with the flow of urine.


The medicine can only be obtained with a prescription.

The recommended dose is one 8-mg capsule once a day. For men with moderate kidney problems, the starting dose should be 4 mg once a day. This may be increased to 8 mg once a day after a week.


This drug is not recommended for patients with severe kidney problems.


The capsules should be taken with food, preferably at the same time every day. They should be swallowed whole, preferably with a glass of water.

The active substance in This drug, silodosin, is an alpha-adrenoreceptor antagonist. It works by blocking receptors called alpha1A adrenoreceptors in the prostate gland, the bladder and the urethra (the tube that leads from the bladder to the outside of the body).

When these receptors are activated, they cause the muscles controlling the flow of urine to contract. By blocking these receptors, silodosin allowsthese muscles to relax, making it easier to pass urine and relieving the symptoms of BPH.

The effects of This drug were first tested in experimental models before being studied in humans.
This drug has been compared with placebo (a dummy treatment) in three main studies involving over 1,800 men with BPH. One of these studies also compared This drug with tamsulosin (another medicine used for BPH).

The main measure of effectiveness in all three studies was the improvement of the patients’ international prostate symptom score (IPSS) after 12 weeks of treatment. IPSS is a rating of the patient’s symptoms such as the inability to empty the bladder, and the urge to urinate repeatedly or to strain while urinating. The patients rated the severity of their symptoms themselves.

This drug was more effective than placebo and as effective as tamsulosin at reducing symptoms of BPH.


In the two studies where This drug was compared only with placebo, the IPSS was around 21 points at the start of the study. After 12 weeks, it had fallen by around 6.4 points in the men who took This drug, and by around 3.5 points in the men who took placebo. In the third study, IPSS was around 19 points before treatment, falling by 7.0 points in the men who took This drug after 12 weeks, 6.7 points in the men who took tamsulosin and 4.7 points in the men who took placebo.

The most common side effect with This drug (seen in more than 1 patient in 10) is a reduction in the amount of semen released during ejaculation. For the full list of all side effects reported with This drug, see the Package Leaflet.

This drug should not be used in people who may be hypersensitive (allergic) to silodosin or any of the other ingredients.

Intra-operative floppy iris syndrome (IFIS) occurs in some patients taking alpha-adrenoreceptor
antagonists and may lead to complications during cataract surgery. IFIS is a condition that makes the
iris floppy.

The Committee for Medicinal Products for Human Use (CHMP) decided that This drug’s benefits are greater than its risks and recommended that it be given marketing authorisation.

The company that makes This drug will ensure that eye surgeons are provided with information on IFIS in all Member States where the medicine will be marketed.

The European Commission granted a marketing authorisation valid throughout the European Union for This drug. on 29 January 2010. The marketing authorisation is valid for five years, after which it can be renewed.


اضغط هنا للقراءة باللغة العربية


Source :

European Medicines Agency






Other Comments

Add a comment

You must sign in to use this servcie

Username:
Password:


facebook comments

Forgot your password


sign up

Consultants Corner

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Dr. Talal Sabouni

Dr. Talal Sabouni UROLOGY AND KIDNEY TRANSPLANT

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist
Poll

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details